---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-015378"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:24:03.587202+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# DiaMedica dosed first patient in ReMEDy2 stroke trial; Q1 cash $46.5M

## Summary
- First participant enrolled in relaunched ReMEDy2 Phase 2/3 trial of DM199 for acute ischemic stroke.
- Cash, equivalents and investments of $46.5M as of March 31, 2024; working capital $44.9M.
- Net cash used in operations was $6.7M in Q1 2024 vs $5.1M in Q1 2023, driven by vendor deposits for ReMEDy2.
- R&D expenses $3.7M (up from $3.6M) and G&A $2.1M (up from $1.9M) compared to year-ago quarter.
- Expect full enrollment for 144-patient interim analysis by Q1 2025; Canadian and Australian site activations on track for H2 2024.

## SEC filing metadata
- accession: 0001437749-24-015378
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774924015378/0001437749-24-015378-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774924015378/dmtp20240507_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-015378
- JSON: https://secwatch.observer/filing/0001437749-24-015378.json
- Plain text: https://secwatch.observer/filing/0001437749-24-015378.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.